Ossica (Ibandronate Sodium Hydrate)

Ibandronate sodium hydrate, the active ingredient in Ossica, is a bisphosphonate presented as a oral tablet for osteoporosis treatment in postmenopausal women and men at risk of fracture. It works to strengthen bone density and reduce fracture risk.

GNH USA supplies Ossica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ossica is a bisphosphonate that acts on bone remodeling pathways to treat skeletal conditions characterized by excessive bone loss. - Post‑menopausal osteoporosis: reduces the oral risk of fractures in the spine and hip. - Male osteoporosis: helps improve bone mineral density and lower the incidence of vertebral fractures. - Glucocorticoid‑induced osteoporosis: mitigates bone loss caused by long‑term steroid therapy. - Paget’s disease of bone : normalises bone‑remodelling turnover and alleviates pain and deform . - Hyper‑t‑ t      ");